0001193125-17-207228.txt : 20170619 0001193125-17-207228.hdr.sgml : 20170619 20170619172203 ACCESSION NUMBER: 0001193125-17-207228 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170616 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20170619 DATE AS OF CHANGE: 20170619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001269021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35935 FILM NUMBER: 17919270 BUSINESS ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-244-6864 MAIL ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d399257d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2017

 

 

Portola Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35935   20-0216859

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

270 E. Grand Avenue

South San Francisco, California

  94080
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 246-7300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders

At the Portola Pharmaceuticals, Inc. (the “Company”) 2017 annual meeting of stockholders held on June 16, 2017, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2017 annual meeting, filed with the Securities and Exchange Commission on April 24, 2017 (the “Proxy Statement”). The results of the matters voted upon at the meeting were:

 

  a) Each of the Class I nominees of the Company’s Board of Directors were elected to hold office until the Company’s 2020 annual meeting of stockholders. The Class I nominees were: Jeffrey W. Bird, M.D., Ph.D.; 41,600,519 shares of Common Stock voted for, 1,122,304 withheld, and 8,383,657 broker non-votes; John H. Johnson; 38,697,578 shares of Common Stock voted for, 4,025,245 withheld, and 8,383,657 broker non-votes; and H. Ward Wolff; 41,613,515 shares of Common Stock voted for, 1,109,308 withheld, and 8,383,657 broker non-votes. The terms of office of Class II directors Dennis Fenton, Ph.D., Charles J. Homcy, M.D. and David Stump, M.D. continue until the Company’s 2018 annual meeting of stockholders. The terms of office of Class III directors Laura Brege, Hollings C. Renton and William Lis continue until the Company’s 2019 annual meeting of stockholders.

 

  b) The stockholders approved, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: 41,927,755 shares of Common Stock voted for, 595,667 against, 199,401 abstaining, and 8,383,657 broker non-votes.

 

  c) The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017: 50,702,428 shares of Common Stock voted for, 293,308 against, 110,744 abstaining, and 0 broker non-votes.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Portola Pharmaceuticals, Inc.
Dated: June 19, 2017    
    By:  

/s/ Mardi C. Dier

      Mardi C. Dier
      Executive Vice President and Chief Financial Officer